Following a four-week public consultation, the EMA this week revised its guidance on methodological considerations for ongoing clinical trials amid the COVID-19 pandemic. The agency also says it will extend its decision to hold all upcoming committee and working party meetings virtually through September 2020. The agency adds that it will continue its practice of holding stakeholder events virtually or postponing them. The EMA first released its methodological guidance in late March, emphasizing the imperative to protect patient safety while charting a course to continue trials throughout the pandemic. Learn More